Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lupin Ltd.

www.lupin.com

Latest From Lupin Ltd.

US Phlow Model And Drug Nationalism: Do Indian Firms Need To Be Watchful?

The new US public benefit pharma manufacturing firm Phlow has received significant federal funding in a bid to improve domestic supply security. Scrip speaks to prominent executives in India's industry over whether this model, if widely replicated, could put at risk the clout and market access plans of the Indian generic industry, a major supplier to the US market. 

Commercial Strategy

COVID-19 Dents Biocon Ahead Of Insulin Opportunity

Biocon’s fourth-quarter earnings were impacted by pandemic-related disruptions, especially its biologics arm, but the Indian firm anticipates a “good recovery.” All eyes will be on the anticipated US launch of biosimilar insulin glargine and its interchangeability status, while the company remains confident of delivering a $1bn FY2022 revenue target for biologics.

Sales & Earnings Biosimilars

COVID-19 Turmoil Dents Biocon In Q4 But Opportunities Including Glargine In Store

Biocon’s fourth quarter earnings were impacted by pandemic-related disruptions, especially its biologics arm, but the Indian firm anticipates a “good recovery”. All eyes will be on the anticipated US launch of biosimilar insulin glargine and its interchangeability status, while the company remains confident of delivering a $1bn FY2022 revenue target for biologics.

Commercial Biosimilars

String Of Positives Lifts Lupin's Outlook

Tentative FDA approval for Lupin’s arformoterol tartrate inhalation solution and a potential European nod for etanercept are seen aiding the company’s prospects in FY2021. Besides, success in a Phase III trial for secnidazole to treat trichomoniasis bodes well, though manufacturing clearances and continuity will also be closely watched.

Manufacturing Policy & Regulation
See All

Company Information

UsernamePublicRestriction

Register